CARDIFF ONCOLOGY, INC. (CRDF) Return on equity 2016–2025
CARDIFF ONCOLOGY, INC. (CRDF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-101.0%FY2025 · since FY2016: -198.3% → -101.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -101.0% | -46.3 pp |
| FY2024 | -54.8% | +4.7 pp |
| FY2023 | -59.4% | -23.0 pp |
| FY2022 | -36.4% | -16.2 pp |
| FY2021 | -20.1% | -5.1 pp |
| FY2020 | -15.1% | +209.4 pp |
| FY2019 | -224.5% | -61.2 pp |
| FY2018 | -163.2% | +219.6 pp |
| FY2017 | -382.8% | -184.5 pp |
| FY2016 | -198.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CRDF financial trends
CRDF RevenueCRDF Net incomeCRDF Net marginCRDF Gross profitCRDF Gross marginCRDF Operating incomeCRDF Operating marginCRDF Operating cash flowCRDF Free cash flowCRDF Capital expendituresCRDF Stock buybacksCRDF Dividends paidCRDF Total assetsCRDF Total liabilitiesCRDF Shareholders’ equityCRDF overview →